GRI Bio (GRI)
Develops NKT-cell therapies for pulmonary fibrosis and autoimmune disease.
Something off on this page? Send us feedback.
Develops GRI-0621 for idiopathic pulmonary fibrosis and GRI-0803 for autoimmune disease by regulating distinct NKT-cell populations. The pre-revenue company retains worldwide rights and expects successful development to support commercialization, licensing, or collaboration economics.
Develops GRI-0621, an oral candidate that inhibits iNKT-cell activity, for idiopathic pulmonary fibrosis, and GRI-0803, an oral activator of dNKT cells, for autoimmune disease, initially systemic lupus erythematosus and lupus nephritis. The former has completed an early clinical trial; the latter remains in IND-enabling development. The company retains worldwide rights and expects future commercialization, licensing, or collaboration economics if its programs succeed.
Operates from La Jolla with a focused internal team while relying on consultants, contract research organizations, contract manufacturers, investigators, and suppliers. Its near-term effort is concentrated on GRI-0621, whose further development requires FDA clearance and substantial capital or a strategic partner; it has no approved product, commercial infrastructure, or significant operating revenue.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $10.9M · Total debt $44.0K · Total assets $11.4M · Shareholders' equity $10.3M
- Revenue
- $0
- Operating income
- −$1.6M
- Net income
- −$1.6M
No dividends on record.
| Institutions6 holders · as of Mar 31, 2026 | 1.29% | 28.2K shares | |
| Otherremainder | 98.71% | 2.16M shares |
2.19M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (2.19M in the company's Sep 3, 2026 report, 89.8K elsewhere); stakes use the report.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Geode Capital Management, LLCInstitution | 0.84% | 18,438 | 13Fas of Mar 31, 2026 |
UBS Group AGInstitution | 0.40% | 8,722 | 13Fas of Mar 31, 2026 |
Tower Research Capital LLC (TRC)Institution | 0.05% | 1,060 | 13Fas of Mar 31, 2026 |
BlackRock, Inc.Institution | 0.00% | 7 | 13Fas of Mar 31, 2026 |
Sbi Securities Co., Ltd.Institution | 0.00% | 4 | 13Fas of Mar 31, 2026 |
| See all 6 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
No open-market trades in the last 12 months.
- Avalyn Pharma
IPF challenge from inhaled nintedanib and combination regimens.
- Contineum Therapeutics
Head-to-head oral small-molecule development in idiopathic pulmonary fibrosis.
- GSK (ADR)
Marketed SLE and lupus-nephritis biologic with global commercial reach.
- Aurinia Pharmaceuticals
Approved oral lupus-nephritis therapy establishes a high clinical bar.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| GRI Bio | $2.00 | 0.00% | $179.7K | — | — | — | — |
| Avalyn Pharma | $36.02 | +1.55% | $1.58B | — | — | — | — |
| Contineum Therapeutics | $17.24 | +4.14% | $648.6M | — | — | — | — |
| GSK (ADR) | $50.65 | +0.45% | $101.06B | 15.8 | 9.1 | 2.2 | +2.7% |
| Aurinia Pharmaceuticals | $16.16 | −0.86% | $2.09B | 7.1 | 21.7 | 6.7 | +18.9% |
| Median | 11.4 | 15.4 | 4.5 | +10.8% |